$GNPX
Genprex Inc Stock $gnpx

$gnpx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000143774924025893 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.849M
YoY Change		19.74%
% of Gross Profit
Research & Development		$1.667M
YoY Change		-58.1%
% of Gross Profit
Depreciation & Amortization		$2.288K
YoY Change		-40.37%
% of Gross Profit
Operating Expenses		$1.667M
YoY Change		-58.1%
Operating Profit		-$6.518M
YoY Change		-18.88%
Interest Expense		$22.44K
YoY Change		-62.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$6.496M
YoY Change		-18.6%
Income Tax
% Of Pretax Income
Net Earnings		-$6.496M
YoY Change		-18.6%
Net Earnings / Revenue
Basic Earnings Per Share		-$3.00
Diluted Earnings Per Share		-$3.01
COMMON SHARES
Basic Shares Outstanding	2.589M	2.099M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$2.459M
YoY Change		-75.3%
Cash & Equivalents		$2.459M
Short-Term Investments
Other Short-Term Assets		$1.936M
YoY Change		-19.69%
Inventory
Prepaid Expenses
Receivables		$0.00
Other Receivables
Total Short-Term Assets		$4.395M
YoY Change		-64.46%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.735K
YoY Change		-88.57%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets		$2.208M
YoY Change		-37.44%
Total Long-Term Assets		$2.210M
YoY Change		-37.66%
TOTAL ASSETS
Total Short-Term Assets		$4.395M
Total Long-Term Assets		$2.210M
Total Assets		$6.605M
YoY Change		-58.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.175M
YoY Change		-21.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.259M
YoY Change		-41.47%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.259M
Total Long-Term Liabilities		$0.00
Total Liabilities		$2.259M
YoY Change		-41.47%
SHAREHOLDERS EQUITY
Retained Earnings		-$146.2M
YoY Change		21.78%
Common Stock		$2.556K
YoY Change		-95.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$4.346M
YoY Change
Total Liabilities & Shareholders Equity		$6.605M
YoY Change		-58.49%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income		-$6.496M
YoY Change		-18.6%
Depreciation, Depletion And Amortization		$2.288K
YoY Change		-40.37%
Cash From Operating Activities		-$5.796M
YoY Change		-28.51%
INVESTING ACTIVITIES
Capital Expenditures		-$17.00K
YoY Change		-185.0%
Acquisitions
YoY Change
Other Investing Activities		-$30.00
YoY Change
Cash From Investing Activities		$16.97K
YoY Change		-184.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		20.76K
YoY Change
NET CHANGE
Cash From Operating Activities		-5.796M
Cash From Investing Activities		16.97K
Cash From Financing Activities		20.76K
Net Change In Cash		-5.758M
YoY Change		-29.15%
FREE CASH FLOW
Cash From Operating Activities		-$5.796M
Capital Expenditures		-$17.00K
Free Cash Flow		-$5.779M
YoY Change		-28.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Genprex, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001595248
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	64.01
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38244
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0772347
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3300 Bee Cave Road, #650-227
	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78746
	dei	City Area Code CityAreaCode	512
	dei	Local Phone Number LocalPhoneNumber	537-7997
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	GNPX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2588546
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2459024	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6737629	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1935787	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	794138	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4394811	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7531767	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1735	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7859	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10000	usd
CY2024Q2	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	2198264	usd
CY2023Q4	gnpx	Research And Development Assets Noncurrent ResearchAndDevelopmentAssetsNoncurrent	2347488	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	773478	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2208264	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3130966	usd
CY2024Q2	us-gaap	Assets Assets	6604810	usd
CY2023Q4	us-gaap	Assets Assets	10670592	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1174800	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1397610	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1084460	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1856598	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2259260	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3254208	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2556	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1486	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150495988	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141103178	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146152994	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133688280	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4345550	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7416384	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6604810	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10670592	usd
CY2024Q2	us-gaap	Depreciation Depreciation	2288	usd
CY2023Q2	us-gaap	Depreciation Depreciation	3837	usd
	us-gaap	Depreciation Depreciation	4958	usd
	us-gaap	Depreciation Depreciation	7853	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1666522	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3976917	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4940902	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9287065	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4849472	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4057197	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7569140	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8007587	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	6518282	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	8037951	usd
	us-gaap	Costs And Expenses CostsAndExpenses	12515000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	17302505	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6518282	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8037951	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12515000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17302505	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	23057	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	55550	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	50771	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	124021	usd
CY2024Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-620	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	2208	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-485	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-4483	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6495845	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-7980193	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12464714	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17182967	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.55
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2161961
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1299505
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1891773
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1268337
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7416384	usd
CY2024Q1	gnpx	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	6793199	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	180720	usd
CY2024Q1	gnpx	Stock Issued During Period Values Reverse Stock Splits StockIssuedDuringPeriodValuesReverseStockSplits	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	335246	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5968869	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	8756680	usd
CY2024Q2	gnpx	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	20762	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	14850	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2049103	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6495845	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4345550	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22274740	usd
CY2023Q1	gnpx	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	4080780	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	21885	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1310230	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9202774	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18484861	usd
CY2023Q2	gnpx	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4400	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1541805	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-7980193	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12050873	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12464714	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17182967	usd
	us-gaap	Depreciation Depreciation	4958	usd
	us-gaap	Depreciation Depreciation	7853	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2579919	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2878320	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	773478	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34852	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1141649	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1921536	usd
	gnpx	Increase Decrease In Research And Development Supplies IncreaseDecreaseInResearchAndDevelopmentSupplies	-149224	usd
	gnpx	Increase Decrease In Research And Development Supplies IncreaseDecreaseInResearchAndDevelopmentSupplies	-93982	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-222810	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1055054	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-772139	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-5096	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11093733	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15039538	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1167	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	gnpx	Payments For Proceeds From Intangible Assets PaymentsForProceedsFromIntangibleAssets	-0	usd
	gnpx	Payments For Proceeds From Intangible Assets PaymentsForProceedsFromIntangibleAssets	39627	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1167	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39627	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6813961	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4080780	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6813961	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4080780	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4278605	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10998385	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6737629	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20954069	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2459024	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9955684	usd
CY2024Q2	gnpx	Intangible Assets Balance Expensed Instead Of Capitalized IntangibleAssetsBalanceExpensedInsteadOfCapitalized	790466	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of Genprex’s unaudited condensed financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></p>
CY2024Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2208989	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6490117	usd
CY2024Q2	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	2198264	usd
CY2023Q4	gnpx	Research And Development Assets Current ResearchAndDevelopmentAssetsCurrent	2347488	usd
CY2024Q2	gnpx	Number Of Granted Patents NumberOfGrantedPatents	21	pure
CY2024Q2	gnpx	Number Of Pending Patent Applications NumberOfPendingPatentApplications	24	pure
CY2024Q1	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	64690
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2555735
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1485902
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	346440
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	57.79
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	53695
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	172.81
CY2024Q1	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	3011751
CY2024Q1	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	2.26
CY2023Q1	gnpx	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	95989
CY2023Q1	gnpx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	44.17
CY2024Q1	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	0
CY2024Q1	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0
CY2023Q1	gnpx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	960
CY2023Q1	gnpx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	250
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3358191
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.93
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	148724
	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	598112
	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0
	gnpx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
	gnpx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2760079
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.22
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	148724
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	64.01
CY2024Q2	gnpx	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	2754975
CY2024Q2	gnpx	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	7.06
CY2023Q2	gnpx	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	143203
CY2023Q2	gnpx	Class Of Warrant Or Right Exercisable Exercise Price ClassOfWarrantOrRightExercisableExercisePrice	59.81
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2760079
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.22
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0452	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8749	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8314	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	284252
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1193
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1631
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	32.4
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1188
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3251
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	285883
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	121.11
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	284377
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	123.19
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2063
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	57.23
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	438
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	32.4
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	285445
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	121.25
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	286440
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	122.72
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1188
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	34.17
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1193
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.75
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	284252
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	121.52
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	287628
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	122.35
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	266213
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	124.64
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	217517
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	126.21
CY2024Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	36529	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	73919	usd
CY2023Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	27758	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	90806	usd

Files In Submission

Name	View Source	Status
0001437749-24-025893-index-headers.html	Edgar Link	pending
0001437749-24-025893-index.html	Edgar Link	pending
0001437749-24-025893.txt	Edgar Link	pending
0001437749-24-025893-xbrl.zip	Edgar Link	pending
ex_677330.htm	Edgar Link	pending
ex_677331.htm	Edgar Link	pending
ex_677332.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gnpx-20240630.xsd	Edgar Link	pending
gnpx20240630_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gnpx-20240630_cal.xml	Edgar Link	unprocessable
gnpx-20240630_def.xml	Edgar Link	unprocessable
gnpx-20240630_lab.xml	Edgar Link	unprocessable
gnpx-20240630_pre.xml	Edgar Link	unprocessable
gnpx20240630_10q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GNPX
Genprex Inc Stock $gnpx

2024 Q3 Form 10-Q Financial Statement

#000143774924025893 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX Genprex Inc Stock $gnpx

2024 Q3 Form 10-Q Financial Statement

#000143774924025893 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GNPX
Genprex Inc Stock $gnpx